Cargando…
Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates
Isorhamnetin is a plant-derived secondary metabolite which belongs to the family of flavonoids. This review summarises the main outcomes described in the literature to date, regarding the effects of isorhamnetin on obesity from in vitro and in vivo studies. The studies carried out in pre-adipocytes...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820709/ https://www.ncbi.nlm.nih.gov/pubmed/36613743 http://dx.doi.org/10.3390/ijms24010299 |
_version_ | 1784865527215161344 |
---|---|
author | González-Arceo, Maitane Gomez-Lopez, Iván Carr-Ugarte, Helen Eseberri, Itziar González, Marcela Cano, M. Pilar Portillo, María P. Gómez-Zorita, Saioa |
author_facet | González-Arceo, Maitane Gomez-Lopez, Iván Carr-Ugarte, Helen Eseberri, Itziar González, Marcela Cano, M. Pilar Portillo, María P. Gómez-Zorita, Saioa |
author_sort | González-Arceo, Maitane |
collection | PubMed |
description | Isorhamnetin is a plant-derived secondary metabolite which belongs to the family of flavonoids. This review summarises the main outcomes described in the literature to date, regarding the effects of isorhamnetin on obesity from in vitro and in vivo studies. The studies carried out in pre-adipocytes show that isorhamnetin is able to reduce adipogenesis at 10 μM or higher doses and that these effects are mediated by Pparγ and by Wnt signalling pathway. Very few studies addressed in rodents are available so far. It seems that treatment periods longer than two weeks are needed by isorhamnetin and its glycosides to be effective as anti-obesity agents. Nevertheless, improvements in glycaemic control can be observed even in short treatments. Regarding the underlying mechanisms of action, although some contradictory results have been found, reductions in de novo lipogenesis and fatty acid uptake could be proposed. Further research is needed to increase the scientific evidence referring to this topic; studies in animal models are essential, as well as randomised clinical trials to determine whether the positive results observed in animals could also be found in humans, in order to determine if isorhamnetin and its glycosides can represent a real tool against obesity. |
format | Online Article Text |
id | pubmed-9820709 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98207092023-01-07 Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates González-Arceo, Maitane Gomez-Lopez, Iván Carr-Ugarte, Helen Eseberri, Itziar González, Marcela Cano, M. Pilar Portillo, María P. Gómez-Zorita, Saioa Int J Mol Sci Review Isorhamnetin is a plant-derived secondary metabolite which belongs to the family of flavonoids. This review summarises the main outcomes described in the literature to date, regarding the effects of isorhamnetin on obesity from in vitro and in vivo studies. The studies carried out in pre-adipocytes show that isorhamnetin is able to reduce adipogenesis at 10 μM or higher doses and that these effects are mediated by Pparγ and by Wnt signalling pathway. Very few studies addressed in rodents are available so far. It seems that treatment periods longer than two weeks are needed by isorhamnetin and its glycosides to be effective as anti-obesity agents. Nevertheless, improvements in glycaemic control can be observed even in short treatments. Regarding the underlying mechanisms of action, although some contradictory results have been found, reductions in de novo lipogenesis and fatty acid uptake could be proposed. Further research is needed to increase the scientific evidence referring to this topic; studies in animal models are essential, as well as randomised clinical trials to determine whether the positive results observed in animals could also be found in humans, in order to determine if isorhamnetin and its glycosides can represent a real tool against obesity. MDPI 2022-12-24 /pmc/articles/PMC9820709/ /pubmed/36613743 http://dx.doi.org/10.3390/ijms24010299 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review González-Arceo, Maitane Gomez-Lopez, Iván Carr-Ugarte, Helen Eseberri, Itziar González, Marcela Cano, M. Pilar Portillo, María P. Gómez-Zorita, Saioa Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title_full | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title_fullStr | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title_full_unstemmed | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title_short | Anti-Obesity Effects of Isorhamnetin and Isorhamnetin Conjugates |
title_sort | anti-obesity effects of isorhamnetin and isorhamnetin conjugates |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820709/ https://www.ncbi.nlm.nih.gov/pubmed/36613743 http://dx.doi.org/10.3390/ijms24010299 |
work_keys_str_mv | AT gonzalezarceomaitane antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT gomezlopezivan antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT carrugartehelen antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT eseberriitziar antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT gonzalezmarcela antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT canompilar antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT portillomariap antiobesityeffectsofisorhamnetinandisorhamnetinconjugates AT gomezzoritasaioa antiobesityeffectsofisorhamnetinandisorhamnetinconjugates |